Vistin Pharma ASA
OSE:VISTN
Vistin Pharma ASA
EPS (Diluted)
Vistin Pharma ASA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
EPS (Diluted)
kr1
|
CAGR 3-Years
36%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Photocure ASA
OSE:PHO
|
EPS (Diluted)
kr0
|
CAGR 3-Years
53%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
20%
|
|
|
N
|
Navamedic ASA
OSE:NAVA
|
EPS (Diluted)
kr0
|
CAGR 3-Years
21%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
EPS (Diluted)
kr0
|
CAGR 3-Years
83%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
Vistin Pharma ASA
Glance View
Vistin Pharma ASA engages in the manufacture and sale of metformin products. The company is headquartered in Oslo, Oslo. The company went IPO on 2015-06-10. The company was created as a result of spin-off of Weifa AS. The company specializes in manufacture of Active Pharmaceutical Ingredients (API) and Solid Dosage Forms. Its products portfolio is comprised of Metformin, Pholcodine and Codeine Phosphate, among others. The firm's products are sold domestically and abroad, including markets in Asia, America, Africa and Europe.
See Also
What is Vistin Pharma ASA's EPS (Diluted)?
EPS (Diluted)
1.4
NOK
Based on the financial report for Dec 31, 2024, Vistin Pharma ASA's EPS (Diluted) amounts to 1.4 NOK.
What is Vistin Pharma ASA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-1%
Over the last year, the EPS (Diluted) growth was 37%. The average annual EPS (Diluted) growth rates for Vistin Pharma ASA have been 36% over the past three years , -1% over the past five years .
You don't have any saved screeners yet